Beta
ManageSearchChatDiscover
271789

AN OVERVIEW OF INCRETIN-BASED THERAPIES: PHARMACOLOGY AND FUTURE PERSPECTIVES

Article

Last updated: 04 Jan 2025

OverviewSimilar Items

Subjects

-

Tags

-

Abstract

Glucagon-like peptide-1 (GLP-1) is a gut-derived incretin hormone that is released upon nutrient ingestion stimulating insulin secretion, suppressing glucagon secretion, and suppressing appetite and food intake which contribute to glucose homeostasis. The incretin system is impaired during type 2 diabetes mellitus (T2DM). Incretin-based therapies are gaining popularity in the clinical field nowadays. Current treatment guidelines for T2DM incorporate glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase 4 inhibitors (DPP-4i) as second-line agents with the advantages of low risk of hypoglycemia with good control of postprandial hyperglycemia (with short-acting GLP-1 RAs and DPP-4i) and weight loss (with GLP-1 RAs). GLP-1 RAs have more efficacy and are preferred with patients with preexisting cardiovascular disease. Growing evidence suggests that incretin-based therapies have beneficial effects on cardiovascular, liver, kidney, and nervous system disorders. The current review includes the biology of the incretin system, the pharmacology of incretin-based therapies, and their applications in experimental and clinical work.  

DOI

10.21608/bfsa.2022.271789

Keywords

Incretin, Glucagon-like peptide-1, Dipeptidyl peptidase 4 inhibitors, Type 2 diabetes mellitus

Authors

First Name

Randa

Last Name

Ismail

MiddleName

-

Affiliation

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University, El-Minia, Egypt

Email

randa.mohamed@mu.edu.eg

City

-

Orcid

-

First Name

Aliaa

Last Name

Anter

MiddleName

-

Affiliation

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University, El-Minia, Egypt

Email

aliaafath2020@gmail.com

City

-

Orcid

-

First Name

I.

Last Name

Matouk

MiddleName

-

Affiliation

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University, El-Minia, Egypt

Email

-

City

-

Orcid

-

First Name

Gehan

Last Name

Heeba

MiddleName

H.

Affiliation

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University, El-Minia, Egypt

Email

ghhh70@yahoo.com

City

-

Orcid

0000-0002-6907-4441

Volume

45

Article Issue

2

Related Issue

37882

Issue Date

2022-12-01

Receive Date

2022-09-02

Publish Date

2022-12-01

Page Start

1,027

Page End

1,042

Print ISSN

1110-0052

Online ISSN

3009-7703

Article File

BFSA_Volume 45_Issue 2_Pages 1027-1042.pdf

PDF . 832.2kB

Link

https://bpsa.journals.ekb.eg/article_271789.html

Detail API

https://bpsa.journals.ekb.eg/service?article_code=271789

Order

271,789

Type

Original Article

Type Code

1,096

Publication Type

Journal

Publication Title

Bulletin of Pharmaceutical Sciences Assiut University

Publication Link

https://bpsa.journals.ekb.eg/

MainTitle

AN OVERVIEW OF INCRETIN-BASED THERAPIES: PHARMACOLOGY AND FUTURE PERSPECTIVES

Details

Type

Article

Created At

22 Jan 2023